Ovarian cancer.

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Pharmacology

Background:

• Ovarian cancer research has led to improved staging and treatment over the past decade.
• Early-stage ovarian cancer patients may not require further therapy, avoiding chemotherapy side effects.
• Advanced ovarian cancer treatment has seen progress with cisplatin-based chemotherapy.

Purpose of the Study:

• To review recent advancements in ovarian cancer management.
• To highlight strategies for improving treatment efficacy and reducing toxicity.
• To discuss novel approaches for overcoming chemotherapy resistance.

Main Methods:

• Analysis of clinical trials in early and advanced ovarian cancer.
• Review of data on dose and dose intensity in chemotherapy.
• Examination of pharmacologic techniques and new cisplatin analogs.
• Evaluation of intraperitoneal cisplatin therapy for residual disease.
• Assessment of experimental models for understanding drug resistance.

Main Results:

• Prospectively identified early-stage patients can avoid adjuvant chemotherapy.
• Cisplatin-based chemotherapy improves response rates and survival in advanced disease.
• High-dose chemotherapy shows promise but increases toxicity; pharmacologic interventions are being developed.
• Intraperitoneal cisplatin may benefit ~30% of patients with residual disease.
• Experimental models aid in understanding and potentially reversing chemotherapy resistance.

Conclusions:

• Treatment stratification for early-stage ovarian cancer can spare patients unnecessary toxicity.
• Optimizing chemotherapy dose and intensity, alongside new drug development, is crucial for advanced disease.
• Pharmacologic strategies and novel agents show potential for overcoming resistance and treating residual disease.